Advanced Cell Technology, Inc. has announced that it has entered into a collaboration agreement with Xgene Corporation to assess the performance of Advanced Cell Technology's dermatology technologies.
In the collaboration, Advanced Cell Technology will provide the human embryonic stem cell-derived skin cells, and Xgene will provide its technology for reconstituting skin from cultured cells, to achieve the mutually beneficial development of advanced in vitro human skin models.
The goal of the collaboration is to test the functionality of embryonic skin cells in regenerating skin for numerous applications in medicine.
"Our expertise in assembling complex multi-tissue constructs from cultured cells offers a solid platform for realizing the therapeutic potential of early progenitor cells, beginning with dermal progenitors," said Warren Hoeffler, Ph.D., Xgene's President and CEO.
"The potential of progenitor cells for healing wounds, and restoring lost functionality to patient skin, while minimizing scarring, could be important for the future practice of dermatology."
"We anticipate that our collaboration with Xgene and the use of their proprietary human skin equivalent technology will accelerate the development of our dermatology products," said Michael West, Ph.D., President and Chief Scientific Officer of Advanced Cell Technology.
William Caldwell, CEO of Advanced Cell Technology said, "We believe that Dr. Hoeffler's vast experience while at Stanford University School of Medicine, Department of Dermatology, has allowed him to commercialize technology that is recognized by the biotech, big pharma and cosmetic industries as revolutionary in nature."
"We look forward to commercializing with Xgene a product derived from human ES cells."